This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
cannabis: Archive
JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales View
by Zacks Equity Research
Jazz Pharmaceuticals beat Q3 2026 revenue and earnings estimates, driven by oncology and rare sleep growth, and raises its full-year sales outlook.
JAZZPositive Net Change TGTXPositive Net Change AMRXPositive Net Change
biotechs cannabis medical
Bull of the Day: Aurora Cannabis (ACB)
by Ethan Feller
Aurora Cannabis stock has moved sharply higher from its recent lows following broad industry developments and fundamental improvements to the core business.
ACBPositive Net Change
cannabis
Zacks Initiates Coverage of Safe Harbor With Neutral Recommendation
by Debanjana Dey
Discover why Zacks rates Safe Harbor as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore SHFS' improving lending economics and expanding financial services offerings amid ongoing losses and regulatory uncertainty.
SHFSNegative Net Change
banking cannabis finance
Aurora Q4 Earnings Call Flags Reset Year as Canada Pressure Weighs
by Zacks Equity Research
ACB frames fiscal 2027 as a reset year as Canadian reimbursement pressure weighs on margins, even as global medical cannabis growth continues.
ACBPositive Net Change
cannabis earnings
Is IIPR a High-Yield Value Play at 6.8x Forward Earnings?
by Moumita C. Chattopadhyay
IIPR offers a 14.9% yield and trades at 6.83x forward earnings as rent recovery efforts and 2026 maturities shape the debate.
SMAPositive Net Change LTCNegative Net Change IIPRNegative Net Change
cannabis finance reit
IIPR and Cannabis Reform: 280E Relief and Schedule III Upside
by Moumita C. Chattopadhyay
IIPR nears an inflection point: Schedule III and 280E relief could boost tenant cash flow, supporting rent stability, re-leasing and growth.
LTCNegative Net Change GTYNegative Net Change IIPRNegative Net Change
cannabis reit
Implied Volatility Surging for Aurora Cannabis Stock Options
by Zacks Equity Research
Investors need to pay close attention to ACB stock based on the movements in the options market lately.
ACBPositive Net Change
cannabis marijuana medical
JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations
by Zacks Equity Research
Jazz Pharmaceuticals beats Q4 earnings and revenue estimates as neuroscience and oncology sales climb, sending shares up 5% in after hours.
JAZZPositive Net Change CSTLNegative Net Change IMCRPositive Net Change
biotechs cannabis earnings medical
Can Cannabis Strength in Canada Drive Canopy's Q3 Earnings?
by Zacks Equity Research
CGC heads into Q3 with Canada cannabis momentum, new product launches and a $50.6M revenue view ahead of Feb. 6 results.
CAHPositive Net Change MMSINegative Net Change VCYTPositive Net Change CGCNegative Net Change
cannabis earnings
TLRY vs. CGC: Which Cannabis Stock is the Better Investment Now?
by Moumi Mondal
Tilray Brands' international revenue surge, beverage scale and strong cash position give it an edge over Canopy Growth as cannabis regulation and demand continue to evolve.
CGCNegative Net Change TLRYPositive Net Change
cannabis medical